Bristol-Myers Squibb (NYSE: BMY) recently received a number of ratings updates from brokerages and research firms:

  • 9/20/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Citigroup Inc. from $75.00 to $70.00. They now have a “buy” rating on the stock.
  • 9/12/2016 – Bristol-Myers Squibb had its “hold” rating reaffirmed by analysts at Jefferies Group. They now have a $57.00 price target on the stock, down previously from $69.00.
  • 9/12/2016 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 9/9/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Barclays PLC from $75.00 to $65.00. They now have an “equal weight” rating on the stock.
  • 9/7/2016 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $75.00 price target on the stock.
  • 9/3/2016 – Bristol-Myers Squibb had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $60.00 price target on the stock.
  • 8/25/2016 – Bristol-Myers Squibb had its “hold” rating reaffirmed by analysts at Morgan Stanley.
  • 8/15/2016 – Bristol-Myers Squibb had its “hold” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $63.00 price target on the stock.
  • 8/13/2016 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Argus. They now have a $90.00 price target on the stock.
  • 8/11/2016 – Bristol-Myers Squibb had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $65.00 price target on the stock, down previously from $79.00.
  • 8/11/2016 – Bristol-Myers Squibb was downgraded by analysts at Berenberg Bank from a “buy” rating to a “hold” rating. They now have a $70.00 price target on the stock, down previously from $80.00.
  • 8/10/2016 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at William Blair.
  • 8/9/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a “buy” rating on the stock.
  • 8/9/2016 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $78.23 price target on the stock.
  • 8/8/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Jefferies Group from $80.00 to $69.00. They now have a “hold” rating on the stock.
  • 8/8/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Deutsche Bank AG from $68.00 to $62.00. They now have a “hold” rating on the stock.
  • 8/8/2016 – Bristol-Myers Squibb had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $65.00 price target on the stock, down previously from $69.00.
  • 8/7/2016 – Bristol-Myers Squibb was downgraded by analysts at Credit Suisse Group AG from an “outperform” rating to a “neutral” rating. They now have a $63.00 price target on the stock, down previously from $86.00.
  • 8/5/2016 – Bristol-Myers Squibb was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Bristol-Myers delivered another strong quarter, wherein both the top and bottom line beat estimates. Robust sales of drugs like Opdivo, Orencia, Eliquis and Sprycel drove top-line growth in the reported quarter. The company raised its 2016 earnings guidance once again buoyed by strong trends across the business, primarily Opdivo and Eliquis, which is encouraging. Meanwhile, we are positive on Bristol-Myers’ efforts to develop its pipeline. It has been working on strengthening its product portfolio as well as pipeline through acquisitions and deals. The company recently announced a couple of clinical trial collaborations with Johnson & Johnson and AbbVie for lung cancer. However, generic competition for several of the company’s key products is concerning. Bristol-Myers expects competition to impact the HCV franchise significantly in the second half of 2016. The company also faces stiff competition in the immuno-oncology space.”
  • 8/5/2016 – Bristol-Myers Squibb was downgraded by analysts at SunTrust Banks Inc. from a “buy” rating to a “neutral” rating. They now have a $68.00 price target on the stock, down previously from $86.00.
  • 8/5/2016 – Bristol-Myers Squibb was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $63.00 price target on the stock.
  • 8/5/2016 – Bristol-Myers Squibb was downgraded by analysts at Deutsche Bank AG from a “hold” rating to a “sell” rating. They wrote, “more than 150 shots-on-goal,” the brokerage sees downside in shares over the next one year if there is lag in revenue momentum and lack of new pipeline “upsides.”That said, Deutsche Bank noted “that one particularly high-profile opportunity, MRK’s BACE inhibitor, could create significant volatility when Phase III studies read out in mid-2017.”Despite expecting continued strong royalty growth from core assets Promacta and Kyprolis, downside, Deutsche said that Kyprolis could face greater competitive pressure as newer entrants in the multiple myeloma market gain traction.Related Link: Opioid Addiction: What To Do When A Loved One Is Hooked, According To ScienceThe notable ones are Johnson & Johnson (NYSE: JNJ)’s Darzalex, Bristol-Myers Squibb Co (NYSE: BMY)’s Empliciti and Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY)’s Ninlaro.”We note that monthly IMS sales growth for Kyprolis has slowed from 40 percent in 1Q16 to 17 percent in 2Q16, with growth in May (18 percent) and June (5 percent) well below the April level (32 percent),” analyst Gregg Gilbert wrote in a note.Among Ligand’s other “Big 6”
  • 8/3/2016 – Bristol-Myers Squibb had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a “buy” rating on the stock.
  • 7/29/2016 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $85.00 price target on the stock.
  • 7/25/2016 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “sell” rating to a “buy” rating. They now have a $78.73 price target on the stock.

Bristol-Myers Squibb Co. (NYSE:BMY) traded up 1.046% during midday trading on Thursday, hitting $56.515. 6,576,289 shares of the stock were exchanged. The firm’s 50-day moving average is $59.04 and its 200 day moving average is $67.58. Bristol-Myers Squibb Co. has a 52 week low of $55.02 and a 52 week high of $77.12. The stock has a market cap of $94.43 billion, a price-to-earnings ratio of 33.050 and a beta of 0.61.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.53 EPS. Equities research analysts expect that Bristol-Myers Squibb Co. will post $2.62 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be paid a $0.38 dividend. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.

In other news, Director Lamberto Andreotti sold 23,200 shares of the company’s stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $72.14, for a total value of $1,673,648.00. Following the sale, the director now owns 403,094 shares in the company, valued at approximately $29,079,201.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.24% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.